<DOC>
	<DOCNO>NCT00039910</DOCNO>
	<brief_summary>Intensive chemotherapy associate significant thrombocytopenia , often require platelet transfusion maintain platelet count . This investigational drug demonstrate increase platelet count . This study test safety efficacy investigational drug prevention thrombocytopenia patient recurrent refractory intermediate-grade high-grade non-Burkitt 's , non-Hodgkin 's lymphoma ( NHL ) , Hodgkin 's disease receiving DHAP ( Dexamethasone , high-dose Cytarabine , Cisplatin ) chemotherapy .</brief_summary>
	<brief_title>Safety Efficacy ( PN-152,243 ) /PN-196,444 Prevention Thrombocytopenia</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Patients must recurrent refractory intermediategrade highgrade nonBurkitt 's , nonHodgkin 's lymphoma ( NHL ) Hodgkin 's disease schedule minimum 2 cycle DHAP ( Dexamethasone , highdose Cytarabine Cisplatin ) chemotherapy Patients must active bleeding ( exclusion apply ) history platelet disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
</DOC>